TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction
Background Blockade of the programmed cell death protein 1 (PD-1) immune checkpoint (ICB) is revolutionizing cancer therapy, but little is known about the mechanisms governing its expression on CD8 T cells. Because PD-1 is induced during activation of T cells, we set out to uncover regulators whose...
Saved in:
| Main Authors: | Gal Markel, Michal J Besser, Eytan Ruppin, Oscar Krijgsman, Daniel S Peeper, Judit Díaz-Gómez, Ettai Markovits, David W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Santiago Duro Sánchez, Juan Simon Nieto, Alex van Vliet, Maarten Altelaar |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/11/e010145.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2.
by: Wenyang Hou, et al.
Published: (2017-01-01) -
Targeting the Cargo Receptor TMED9 as a Therapeutic Strategy Against Brain Tumors
by: Alaa Daoud Sarsour, et al.
Published: (2025-05-01) -
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
by: Marjon A Smit, et al.
Published: (2014-12-01) -
Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy
by: Zhuangzhi Wang, et al.
Published: (2025-05-01) -
TMED9: a potential therapeutic target and prognostic marker in glioma and its implications across pan-cancer contexts
by: Benyong Mi, et al.
Published: (2025-03-01)